81 related articles for article (PubMed ID: 20089653)
1. Disulfide reduction in CD4 domain 1 or 2 is essential for interaction with HIV glycoprotein 120 (gp120), which impairs thioredoxin-driven CD4 dimerization.
Cerutti N; Killick M; Jugnarain V; Papathanasopoulos M; Capovilla A
J Biol Chem; 2014 Apr; 289(15):10455-10465. PubMed ID: 24550395
[TBL] [Abstract][Full Text] [Related]
2. HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth.
Fries CN; Chen JL; Dennis ML; Votaw NL; Eudailey J; Watts BE; Hainline KM; Cain DW; Barfield R; Chan C; Moody MA; Haynes BF; Saunders KO; Permar SR; Fouda GG; Collier JH
Sci Rep; 2021 Jul; 11(1):14494. PubMed ID: 34262096
[TBL] [Abstract][Full Text] [Related]
3. Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?
Klasse PJ; Ozorowski G; Sanders RW; Moore JP
Cell Host Microbe; 2020 Apr; 27(4):507-518. PubMed ID: 32272076
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms.
Ho JK; Jeevan-Raj B; Netter HJ
Viruses; 2020 Jan; 12(2):. PubMed ID: 31973017
[No Abstract] [Full Text] [Related]
5. Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin.
Ringe RP; Cruz Portillo VM; Dosenovic P; Ketas TJ; Ozorowski G; Nogal B; Perez L; LaBranche CC; Lim J; Francomano E; Wilson IA; Sanders RW; Ward AB; Montefiori DC; Nussenzweig MC; Klasse PJ; Cupo A; Moore JP
J Virol; 2020 Feb; 94(6):. PubMed ID: 31852794
[TBL] [Abstract][Full Text] [Related]
6. Oral immunotherapy tolerizes mice to enzyme replacement therapy for Morquio A syndrome.
Sosa AC; Kariuki B; Gan Q; Knutsen AP; Bellone CJ; Guzmán MA; Barrera LA; Tomatsu S; Chauhan AK; Armbrecht E; Montaño AM
J Clin Invest; 2020 Mar; 130(3):1288-1300. PubMed ID: 31743109
[TBL] [Abstract][Full Text] [Related]
7. Reduced immunogenicity of Plasmodium falciparum gamete surface antigen (Pfs48/45) in mice after disruption of disulphide bonds - evaluating effect of interferon-γ-inducible lysosomal thiol reductase.
Merino KM; Bansal GP; Kumar N
Immunology; 2016 Aug; 148(4):433-47. PubMed ID: 27177843
[TBL] [Abstract][Full Text] [Related]
8. CD4+ T-cell epitope prediction using antigen processing constraints.
Mettu RR; Charles T; Landry SJ
J Immunol Methods; 2016 May; 432():72-81. PubMed ID: 26891811
[TBL] [Abstract][Full Text] [Related]
9. The Cellular Localization of Human Cytomegalovirus Glycoprotein Expression Greatly Influences the Frequency and Functional Phenotype of Specific CD4+ T Cell Responses.
Pachnio A; Zuo J; Ryan GB; Begum J; Moss PA
J Immunol; 2015 Oct; 195(8):3803-15. PubMed ID: 26363059
[TBL] [Abstract][Full Text] [Related]
10. Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.
Hyakumura M; Walsh R; Thaysen-Andersen M; Kingston NJ; La M; Lu L; Lovrecz G; Packer NH; Locarnini S; Netter HJ
J Virol; 2015 Nov; 89(22):11312-22. PubMed ID: 26339047
[TBL] [Abstract][Full Text] [Related]
11. Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.
Sabahi A; Uprichard SL; Wimley WC; Dash S; Garry RF
J Virol; 2014 Sep; 88(18):10280-8. PubMed ID: 24991010
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of contributions from protein conformational stability and major histocompatibility complex class II-peptide binding affinity to CD4+ epitope immunogenicity in HIV-1 envelope glycoprotein.
Li T; Steede NK; Nguyen HN; Freytag LC; McLachlan JB; Mettu RR; Robinson JE; Landry SJ
J Virol; 2014 Sep; 88(17):9605-15. PubMed ID: 24920818
[TBL] [Abstract][Full Text] [Related]
13. Shaping T cell - B cell collaboration in the response to human immunodeficiency virus type 1 envelope glycoprotein gp120 by peptide priming.
Steede NK; Rust BJ; Hossain MM; Freytag LC; Robinson JE; Landry SJ
PLoS One; 2013; 8(6):e65748. PubMed ID: 23776539
[TBL] [Abstract][Full Text] [Related]
14. CD4 T-cell memory responses to viral infections of humans show pronounced immunodominance independent of duration or viral persistence.
Jing L; Schiffer JT; Chong TM; Bruckner JJ; Davies DH; Felgner PL; Haas J; Wald A; Verjans GM; Koelle DM
J Virol; 2013 Mar; 87(5):2617-27. PubMed ID: 23255792
[TBL] [Abstract][Full Text] [Related]
15. The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles.
Kim HJ; Lim SJ; Kwag HL; Kim HJ
PLoS One; 2012; 7(4):e35893. PubMed ID: 22563414
[TBL] [Abstract][Full Text] [Related]
16. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?
Klasse PJ; Sanders RW; Cerutti A; Moore JP
AIDS Res Hum Retroviruses; 2012 Jan; 28(1):1-15. PubMed ID: 21495876
[TBL] [Abstract][Full Text] [Related]
17. Influence of disulfide-stabilized structure on the specificity of helper T-cell and antibody responses to HIV envelope glycoprotein gp120.
Mirano-Bascos D; Steede NK; Robinson JE; Landry SJ
J Virol; 2010 Apr; 84(7):3303-11. PubMed ID: 20089653
[TBL] [Abstract][Full Text] [Related]
18. Conformational instability governed by disulfide bonds partitions the dominant from subdominant helper T-cell responses specific for HIV-1 envelope glycoprotein gp120.
Nguyen HN; Steede NK; Robinson JE; Landry SJ
Vaccine; 2015 Jun; 33(25):2887-96. PubMed ID: 25944298
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
